Skip to main content
. 2013 Apr 16;13:193. doi: 10.1186/1471-2407-13-193

Table 4.

Gain in response rate vs gain in survival for anticancer drugs approved by FDA 2002-2012

Drug Tumor type Gain in response rate p Gain in OS, months p
Oxaliplatin [156,171]
Colorectal
48% vs 32%
0.006
5.6
<0.001
Pemetrexed [157]
Mesothelioma
41.3% vs 16.7%
<0.0001
2.8
0.02
Bevacizumab [152]
Colorectal
44.8% vs 34.8%
0.004
4.7
<0.0001
Gemcitabine [158]
Breast
41.4% vs 26.2%
0.0002
2.8
0.0489
Erlotinib [37]
Pancreas
8.6% vs 8%
NSa
0.33
0.038
Docetaxel [159]
Gastric
37% vs 25%
0.01
1.9
<0.001
Topotecan [160]
Cervix
27% vs 13%
0.004
2.9
0.017
Bevacizumab [153]
Colorectal
22.7% vs 8.6%
<0.0001
2.1
0.0011
Gemcitabine [161]
Ovary
42.7% vs 30.9%
0.0016
0.7
0.83b
Bevacizumab [151]
NSCLC
35% vs 15%
<0.001
2
0.003
Docetaxel [162]
Head and Neck
68% vs 54%
0.006
3.3
0.02
Lapatinib [163]
Breast
22% vs 14%
0.09
NAc
0.72 b
Lapatinib [164]
Breast
23.7% vs 13.9%
0.017
0.3
0.18 b
Temsirolimus [165]
Renal
8.1% vs 4.8%
NS
1.1
0.70 b
Ixabepilone [166,167]
Breast
35% vs 14%
<0.0001
1.8
0.19 b
Bevacizumab [154,155]
Renal
31% vs 13%
0.0001
2.0
0.33 b
Lapatinib [168]
Breast (Her-2/neu +ve)
28% vs 15%
0.021
1.0
0.11 b
Trastuzumab [169]
Gastroesophageal
47% vs 35%
0.0017
2.7
0.0046
Cetuximab [170] Head and neck 36% vs 20% <0.001 2.7 0.04

a. NS: not significant.

b. PFS differed significantly.

c. NA: not available.